ARTICLE | Management Tracks
Pfizer seeking successor as Dolsten prepares to step down from R&D role
Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
July 10, 2024 1:22 AM UTC
Pfizer Inc. (NYSE:PFE) said it is looking for a successor for Mikael Dolsten as he prepares to step down from his role as CSO and president of R&D. Dolsten has been with the pharma since 2009; he was president of research at Wyeth, which Pfizer acquired that year.
The company credited Dolsten with drug and vaccine approvals across numerous therapeutic areas, with the rapid development of COVID-19 vaccine Comirnaty and antiviral Paxlovid nirmatrelvir/ritonavir as crowning achievements...